[HTML][HTML] Poorly differentiated thyroid carcinoma: a clinician's perspective
J Tong, M Ruan, Y Jin, H Fu, L Cheng… - European Thyroid …, 2022 - etj.bioscientifica.com
Poorly differentiated thyroid carcinoma (PDTC) is a rare thyroid carcinoma originating from
follicular epithelial cells. No explicit consensus can be achieved to date due to sparse …
follicular epithelial cells. No explicit consensus can be achieved to date due to sparse …
The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and …
Y Ito, N Onoda, T Okamoto - Endocrine journal, 2020 - jstage.jst.go.jp
Abstract The Japan Associations of Endocrine Surgeons has developed the revised version
of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines …
of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines …
[HTML][HTML] Poorly differentiated thyroid carcinoma: An underdiagnosed entity
MS Dettmer, A Schmitt, P Komminoth, A Perren - Der Pathologe, 2020 - ncbi.nlm.nih.gov
Poorly differentiated thyroid carcinoma - PMC Back to Top Skip to main content NIH NLM
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation …
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact
M Volante, I Rapa, M Gandhi, G Bussolati… - The Journal of …, 2009 - academic.oup.com
Context: Poorly differentiated carcinomas represent an aggressive group of thyroid tumors
with controversial classification placement and poorly understood pathogenesis. Molecular …
with controversial classification placement and poorly understood pathogenesis. Molecular …
[HTML][HTML] Antioxidant and antigrowth action of peracetylated oleuropein in thyroid cancer cells
S Bulotta, R Corradino, M Celano… - Journal of …, 2013 - jme.bioscientifica.com
The diagnosis of conventional and oncocytic poorly differentiated (oPD) thyroid carcinomas
is difficult. The aim of this study is to characterise their largely unknown miRNA expression …
is difficult. The aim of this study is to characterise their largely unknown miRNA expression …
[HTML][HTML] MicroRNA profile of poorly differentiated thyroid carcinomas–new diagnostic and prognostic insights
MS Dettmer, A Perren, H Moch… - Journal of molecular …, 2014 - ncbi.nlm.nih.gov
The diagnosis of conventional and oncocytic poorly differentiated thyroid carcinomas is
difficult. The aim of this study was to characterize their largely unknown miRNA expression …
difficult. The aim of this study was to characterize their largely unknown miRNA expression …
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian …
We investigated the genotype-dependent therapeutic potential of targeting the
phosphoinositide 3-kinase (PI3K)/Akt pathway for thyroid cancer. Proliferation of TPC1 …
phosphoinositide 3-kinase (PI3K)/Akt pathway for thyroid cancer. Proliferation of TPC1 …
Poorly differentiated thyroid carcinomas: how much poorly differentiated is needed?
M Dettmer, A Schmitt, H Steinert… - The American journal …, 2011 - journals.lww.com
Background: Poorly differentiated (PD) carcinomas of the thyroid are conceptually situated
between well-differentiated (papillary or follicular) carcinomas and anaplastic thyroid …
between well-differentiated (papillary or follicular) carcinomas and anaplastic thyroid …
Cytomorphologic features of poorly differentiated thyroid carcinoma: a multi‐institutional analysis of 40 cases
M Bongiovanni, L Bloom, JF Krane… - Cancer …, 2009 - Wiley Online Library
BACKGROUND: Poorly differentiated thyroid carcinoma (PDTC) is an uncommon and
aggressive malignancy. Despite the significant clinical implications of a diagnosis of PDTC …
aggressive malignancy. Despite the significant clinical implications of a diagnosis of PDTC …
Clinical trials for progressive differentiated thyroid cancer: patient selection, study design, and recent advances
M Schlumberger, SI Sherman - Thyroid, 2009 - liebertpub.com
Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine
and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular …
and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular …